MEDPACE HOLDINGS, INC. (NASDAQ:MEDP) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
On May 1, 2017, Medpace Holdings, Inc. (the Company) issued a
press release announcing its financial results for the three
months ended March 31, 2017. The full text of the press release
was posted on the Companys internet website and is furnished as
Exhibit 99.1 hereto and incorporated herein by reference.
to General Instruction B.2 of Current Report on Form 8-K, the
information contained in, or incorporated into, Item 2.02,
including the press release attached as Exhibit 99.1, is being
furnished and shall not be deemed filed for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference
into any registration statement or other filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference to such
filing.
Item 8.01 Other Events.
On April 27, 2017, the Companys Board of Directors authorized a
share repurchase program of up to $50 million of the Companys
common stock in the open market or negotiated transactions, at
the discretion of the Companys management. The extent and timing
of repurchases depends on market conditions, applicable
regulatory requirements, and other considerations. The share
repurchase program does not obligate the Company to acquire any
minimum amount of common stock and the program may be modified,
limited, extended, suspended or terminated at any time at the
Companys discretion. The Company currently expects that the
repurchases under the program will be made in compliance with the
SECs Rule 10b-18.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press release dated May 1, 2017 |
About MEDPACE HOLDINGS, INC. (NASDAQ:MEDP)
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia. MEDPACE HOLDINGS, INC. (NASDAQ:MEDP) Recent Trading Information
MEDPACE HOLDINGS, INC. (NASDAQ:MEDP) closed its last trading session up +0.68 at 32.39 with 121,650 shares trading hands.